88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
WHO recommends global use of newest hepatitis C drugs, urges price reductions
Interferon-free BMS combo cures 90% of genotype 1 hepatitis C
Merck combination suppresses HCV in mono-infected and co-infected patients
Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b
Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients
AbbVie '3D' combination cures 99% of genotype 1b hepatitis C
Simeprevir cures almost 80% of first-time co-infected hepatitis C patients
